July 2017

ICON acquires Mapi Group

Monday, July 31, 2017

Icon, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has acquired the Mapi Group, a Patient-Centered Health Outcomes Research and Commercialization company.

[Read More]

LabCorp to acquire Chiltern for $1.2B in cash

Monday, July 31, 2017

LabCorp, a global life sciences company, and Chiltern, a specialty CRO, announced that LabCorp will acquire Chiltern pursuant to a definitive agreement with Chiltern’s shareholders in an all-cash transaction valued at approximately $1.2 billion. Once the transaction is complete, Chiltern will become part of LabCorp’s Covance segment.

[Read More]

The call for patient feedback

Monday, July 31, 2017

The Pulse on Patient Recruitment by Ashley Tointon

Having a patient-centered approach is a positive trend in sponsored clinical trials as more companies reach out to seek input from patients. Pa­tient feedback can assist protocol developers in the creation of clinical trials that are more appealing to study volunteers. The input that patients are providing may be just as expected or it may be completely surpris­ing, yet incorporating the feedback into a fully developed strategy or protocol is not an easy task.

[Read More]

Crohn’s & Colitis Foundation launch Clinical Trials Community

Monday, July 31, 2017

On July 20, 2017, the Crohn’s & Colitis Foundation launched a Clinical Trials Community (the Community) for the education of patients, family members, caregivers and healthcare providers regarding the study of irritable bowel disease (IBD). Specifically, the community will provide education on the clinical trial process as well as its value for facilitating improvements in care. Subsequently, this process may help reduce barriers to patient enrollment in IBD clinical trials, thereby enabling faster routes to therapeutic discovery.

[Read More]

AstraZeneca, Merck to partner

Friday, July 28, 2017

AstraZeneca and Merck & Co., Inc. have announced that they have entered a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Lynparza is an innovative, first-in-class oral poly ADP ribose polymerase (PARP) inhibitor currently approved for BRCA-mutated ovarian cancer in multiple lines of treatment.

[Read More]